Autologous Killer Cell Therapy in Colon Cancer Patients
Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients
This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups. Patients in both groups will receive the same therapeutic regimen as usual. Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.
Immune-cell therapy with CIK cells
Routine treatments for colon cancer patients according to their stage
Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
Patients who receive routine treatments only (chemotherapy, radiation therapy)
Inclusion Criteria: Patients with histologically confirmed colorectal cancer at stage IV ECOG performance status 0-2 Adequate cardiac/renal/hepatic function Adequate bone marrow function (blood cell count) Exclusion Criteria: Patients that have received prior chemotherapy or immune cell therapy Patients that have previously participated in another clinical trial History of positive test result for HIV, HBV, HCV, HTLV-1, syphilis Presence of Active infections Patients with immunodeficiencies, autoimmunities, or severe allergies Receiving immunosuppressive regimens